The recent interim results of the phase I-II DANTE trial showed that adding atezolizumab to FLOT led to improved tumor downsizing and pCR rates (24 vs 15%; one-sided P = 0.032) Of note, regression rates further improved with higher PD-L1 expression (33 vs 12% in tumors with CPS ≥ 10) or in MSI-high tumors (63 vs 27%) [12]. This evidence concerns the gene CD274 and neoplasm.